Eyebiotech Limited
acquired
acquired
Stage
About
Eyebiotech Limited is a clinical-stage ophthalmology biotechnology company developing a next-generation pipeline of therapies for back-of-the-eye diseases. The company was acquired by Merck in 2024.
Explore Eyebiotech Limited's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.